Compass Pathways PLC (CMPS)
6.67
+0.01
(+0.15%)
USD |
NASDAQ |
Jun 17, 09:46
Compass Pathways Enterprise Value: 221.62M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 221.62M |
| June 13, 2024 | 240.77M |
| June 12, 2024 | 233.93M |
| June 11, 2024 | 203.16M |
| June 10, 2024 | 214.10M |
| June 07, 2024 | 240.77M |
| June 06, 2024 | 238.71M |
| June 05, 2024 | 277.01M |
| June 04, 2024 | 290.68M |
| June 03, 2024 | 285.90M |
| May 31, 2024 | 270.85M |
| May 30, 2024 | 273.59M |
| May 29, 2024 | 275.64M |
| May 28, 2024 | 274.96M |
| May 24, 2024 | 277.69M |
| May 23, 2024 | 276.32M |
| May 22, 2024 | 296.15M |
| May 21, 2024 | 304.36M |
| May 20, 2024 | 307.78M |
| May 17, 2024 | 302.31M |
| May 16, 2024 | 312.57M |
| May 15, 2024 | 332.40M |
| May 14, 2024 | 324.87M |
| May 13, 2024 | 321.45M |
| May 10, 2024 | 303.68M |
| Date | Value |
|---|---|
| May 09, 2024 | 350.17M |
| May 08, 2024 | 347.44M |
| May 07, 2024 | 350.17M |
| May 06, 2024 | 354.96M |
| May 03, 2024 | 349.16M |
| May 02, 2024 | 330.03M |
| May 01, 2024 | 345.75M |
| April 30, 2024 | 351.90M |
| April 29, 2024 | 320.46M |
| April 26, 2024 | 308.84M |
| April 25, 2024 | 303.37M |
| April 24, 2024 | 319.78M |
| April 23, 2024 | 330.03M |
| April 22, 2024 | 337.55M |
| April 19, 2024 | 338.91M |
| April 18, 2024 | 341.65M |
| April 17, 2024 | 349.16M |
| April 16, 2024 | 366.25M |
| April 15, 2024 | 334.81M |
| April 12, 2024 | 358.05M |
| April 11, 2024 | 393.59M |
| April 10, 2024 | 392.90M |
| April 09, 2024 | 420.24M |
| April 08, 2024 | 431.86M |
| April 05, 2024 | 415.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
43.69M
Minimum
May 11 2022
1.931B
Maximum
Dec 23 2020
618.76M
Average
372.46M
Median
Sep 21 2023
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 114.47M |
| Biodexa Pharmaceuticals Plc | 1.287M |
| Verona Pharma PLC | 1.021B |
| NuCana PLC | -9.447M |
| Autolus Therapeutics PLC | 438.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.19M |
| Total Expenses (Quarterly) | 35.47M |
| EPS Diluted (Quarterly) | -0.55 |
| Earnings Yield | -35.16% |